These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 12060981
1. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. Attarbaschi A, Mann G, Dworzak M, Urban C, Fink FM, Dieckmann K, Riehm H, Gadner H, Austrian Cooperative Study Group. Wien Klin Wochenschr; 2002 Feb 28; 114(4):148-57. PubMed ID: 12060981 [Abstract] [Full Text] [Related]
2. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H. Klin Padiatr; 1998 Feb 28; 210(4):192-9. PubMed ID: 9743952 [Abstract] [Full Text] [Related]
3. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000. Attarbaschi A, Mann G, Dworzak M, Trebo M, Urban C, Fink FM, Horcher E, Reiter A, Riehm H, Gadner H, Austrian Cooperative Study Group. Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):978-86. PubMed ID: 12635465 [Abstract] [Full Text] [Related]
4. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891 [Abstract] [Full Text] [Related]
5. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group. J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980 [Abstract] [Full Text] [Related]
7. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G. J Clin Oncol; 2005 Nov 01; 23(31):7942-50. PubMed ID: 16258094 [Abstract] [Full Text] [Related]
8. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, Bender-Götze C, Dörffel W, Dopfer R, Frey E. Klin Padiatr; 1994 Nov 01; 206(4):208-21. PubMed ID: 7526027 [Abstract] [Full Text] [Related]
9. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, Fink FM, Meister B, Schmitt K, Dieckmann K, Henze G, Haas OA, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol; 2009 Feb 01; 144(4):559-70. PubMed ID: 19077160 [Abstract] [Full Text] [Related]
10. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M. Klin Padiatr; 2005 Feb 01; 217(6):310-20. PubMed ID: 16307416 [Abstract] [Full Text] [Related]
11. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. J Clin Oncol; 2006 Dec 20; 24(36):5742-9. PubMed ID: 17179108 [Abstract] [Full Text] [Related]
13. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M. Leukemia; 2010 Feb 20; 24(2):265-84. PubMed ID: 20010625 [Abstract] [Full Text] [Related]
14. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M. J Clin Oncol; 2005 Oct 01; 23(28):7161-7. PubMed ID: 16192600 [Abstract] [Full Text] [Related]
15. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, Pötschger U, Ullmann R, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer R, Strehl S, Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol; 2010 Jan 01; 148(2):293-300. PubMed ID: 19821827 [Abstract] [Full Text] [Related]
16. Evolution of BFM trials for childhood ALL. Schrappe M. Ann Hematol; 2004 Jan 01; 83 Suppl 1():S121-3. PubMed ID: 15124702 [Abstract] [Full Text] [Related]
17. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G. J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690 [Abstract] [Full Text] [Related]
18. Treatment outcome of adolescents with acute lymphoblastic leukemia. Irken G, Oren H, Gülen H, Duman M, Uçar C, Atabay B, Yilmaz S, Uysal K, Cevik N. Ann Hematol; 2002 Nov 01; 81(11):641-5. PubMed ID: 12454702 [Abstract] [Full Text] [Related]
19. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, Egurbide I, Hernández Rivas JM, Rivas C, Alcalá A, Besalduch J, Maciá J, Gardella S, Carnero M, Lite JM, Casanova F, Martinez M, Fontanillas M, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatías Malignas. Haematologica; 2001 Jun 01; 86(6):586-95. PubMed ID: 11418367 [Abstract] [Full Text] [Related]
20. [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991]. Zintl F, Malke H, Reimann M, Hermann J, Domula M, Dörffel W, Eggers G, Exadaktylos P, Hilgenfeld E, Kotte W. Klin Padiatr; 1992 Jun 01; 204(4):221-9. PubMed ID: 1518257 [Abstract] [Full Text] [Related] Page: [Next] [New Search]